The Latest Cardiac and Vascular News
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously announced $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics. Under the terms of the agreement, Alnylam will receive up to […]
– RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and Drug Development Today with Potential to Transform Lives of Patients – – Blackstone Provides a Customized Investment at Scale to Enable Alnylam to Achieve Self-sustainable Financial Profile Without Need for Future Equity Financing – – […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of […]
